Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.76 |
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24894102 | 0.98 | MGLL (0.80) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL15834900 | 0.98 | MGLL (0.80) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL16255466 | 0.98 | MGLL (0.80) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL13014804 | 0.98 | MGLL (0.80) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL19195275 | 0.98 | MGLL (0.80) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL407969 | 0.89 | MGLL (0.95) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL14524209 | 0.88 | MGLL (0.60) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL19410574 | 0.88 | MGLL (0.70) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL140275 | 0.87 | MGLL (1.00) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL9643398 | 0.87 | MGLL (1.00) | MGLLFAAHPTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044554-A1 | VHH ANTIBODY CONJUGATES WITH HETEROARYL CHELATORS | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023220280-A1 | RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023201336-A2 | HUMANIZED MULTIVALENT PROTEIN CONJUGATES | VALITOR, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023201335-A2 | PURIFIED MULTIVALENT PROTEIN-HYALURONIC ACID POLYMER CONJUGATES | VALITOR, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11352348-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-3828196-A1 | METHOD FOR PREPARING ANTIBODY-DRUG CONJUGATE INTERMEDIATE BY MEANS OF ACID METHOD AND APPLICATION THEREOF | Mabplex International, Ltd. (CN) | 2021-06-02 | — | — | EP | disclosed |
| US-20210101888-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-04-08 | — | — | US | disclosed |
| US-7846896-B2 | PEG conjugates of NK4 | HOFFMAN-LA ROCHE INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | NATIONAL SCIENCE FOUNDATION | 2010-10-07 | — | — | US | disclosed |
| US-20090118476-A1 | Purification of pegylated polypeptides | HOFFMANN-LA ROCHE INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090101585-A1 | regeneration of a cation exchange chromatography column for purification of polypeptides | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7459436-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459429-B2 | Method of treating disturbances of iron distribution in inflammatory intestinal diseases | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459435-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | BRANDT MICHAEL | 2008-04-10 | — | — | US | disclosed |
| US-7202208-B2 | Erythropoietin composition | HOFFMAN-LA ROCHE INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7169754-B2 | Erythropoietin composition | HOFFMANN-LA ROCHE INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | PTMS, CHAMP1, RAB5IF | MGLL 2648/4885FAAH 1005/4885PTGS1 2733/4885 |
| US-11352348-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | MGLL 4600/4885FAAH 4427/4885PTGS1 3783/4885 |
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | MGLL 3181/4885FAAH 3777/4885PTGS1 3480/4885 |
| US-20210101888-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, RBM22, SF3B1 | MGLL 4600/4885FAAH 4427/4885PTGS1 3783/4885 |
| US-20090118476-A1 | Purification of pegylated polypeptides | EPOR, HAMP, EGFR | MGLL 2152/4885FAAH 4329/4885PTGS1 2793/4885 |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | PBK, IL4, CD47 | MGLL 1850/4885FAAH 4171/4885PTGS1 1280/4885 |
| US-20090101585-A1 | regeneration of a cation exchange chromatography column for purification of polypeptides | IAPP, HDGF, HGF | MGLL 3689/4885FAAH 4535/4885PTGS1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.